CARLOMAGNO, FRANCESCA
CARLOMAGNO, FRANCESCA
DIPARTIMENTO DI MEDICINA MOLECOLARE E BIOTECNOLOGIE MEDICHE
Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2).
2003 Carlomagno, F; Vitagliano, D; Guida, T; Basolo, F; Castellone, Md; Melillo, ROSA MARINA; Fusco, Alfredo; Santoro, Massimo
Genetic Alterations in differentiated thyroid cancer:what can be expected for gene expression profiling of thyroid carcinomas
2003 Santoro, Massimo; Melillo, ROSA MARINA; Carlomagno, Francesca; Castellone, MARIA DOMENICA; Vitagliano, Donata; Guida, Teresa; Vecchio, Giancarlo; Fusco, Alfredo
The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes
2002 Carlomagno, Francesca; Vitagliano, Donata; Guida, Teresa; Napolitano, M.; Vecchio, Giancarlo; Fusco, Alfredo; Gazit, A.; Levitzki, A.; Santoro, Massimo
The Insulin Receptor Substrate (IRS)-1 recruits Phosphatidylinositol 3-Kinase to Ret: evidence for a competition between Shc and IRS-1 for the binding to Ret.
2001 Melillo, ROSA MARINA; Carlomagno, Francesca; DE VITA, Gabriella; Formisano, Pietro; Vecchio, Giancarlo; Fusco, Alfredo; Billaud, M.; Santoro, Massimo
Constitutive and AP20187-induced ret activation in photoreceptors does not protect from light-induced damage
2007 M., Allocca; U., Di Vicino; M., Petrillo; F., Carlomagno; L., Domenici; Auricchio, Alberto; Carlomagno, Francesca
Basi molecolari delle nuove terapie: inibitori delle protein-chinasi.
2007 Santoro, Massimo; Salvatore, G.; Carlomagno, F.; Fusco, Alfredo
Therapeutic strategies to target the receptor tyrosine kinase AXL in thyroid cancer
2012 Gnanaprakasam, Krisnamoorthy; Guida, Teresa; Visciano, Carla; Liotti, Federica; Carlomagno, Francesca; Melillo, ROSA MARINA
Ret-mediated mitogenesis requires Src kinase activity.
1999 Melillo, Rm; Barone, MARIA VITTORIA; Lupoli, G; Cirafici, Am; Carlomagno, F; Visconti, R; Matoskova, B; Di Fiore, Pp; Vecchio, G; Fusco, A; Santoro, M.
Receptor tyrosine kinase inhibitors in thyroid cancer.
2008 Castellone, Md; Carlomagno, Francesca; Salvatore, G; Santoro, Massimo
Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer.
2013 De Falco, V; Buonocore, Preziosa; Muthu, M; Torregrossa, L; Basolo, F; Billaud, M; Gozgit, Jm; Carlomagno, Francesca; Santoro, Massimo
Pros and cons of cellular studies in developing new drugs for thyroid cancers
2008 Salvatore, G.; Carlomagno, Francesca; Santoro, Massimo
Attacking cancer with molecularly targeted agents
2013 Santoro, Massimo; Carlomagno, Francesca
Activation of RET as a dominant transforming gene by germline mutatios of MEN2A and MEN2B
1995 Santoro, Massimo; Carlomagno, Francesca; A., Romano; D. D., Bottaro; N. A., Dathan; M., Grieco; Fusco, Alfredo; Vecchio, Giancarlo; B., Matoskova; M. H., Kraus; P. P., Di Fiore
Tyrosine 1062 of RET-MEN2A mediates activation of Akt (protein kinase B) and mitogen-activated protein kinase pathways leading to PC12 cell survival
2000 DE VITA, Gabriella; Melillo, ROSA MARINA; Carlomagno, Francesca; Visconti, R; Castellone, Md; Bellacosa, A; Billaud, M; Fusco, Alfredo; Tsichlis, Pn; Santoro, M.
Determination of the frequency of the common 657Del5 Nijmegen breakage syndrome mutation in the German population: no association with risk of breast cancer
1999 Carlomagno, Francesca; CHANG CLAUDE, J; Dunning, Am; Ponder, Baj
Mutations in the extracellular domain cause RET loss of function by a dominant negative mechanism
1998 Cosma, Mp; Cardone, M; Carlomagno, Francesca; Colantuoni, V.
Signalling of the Ret receptor tyrosine kinase through the c-Jun N-terminal Protein Kinases (JNKs): evidence for a divergence of the ERKs and JNKs pathways induced by Ret
1998 Chiariello, M; Visconti, R; Carlomagno, Francesca; Melillo, ROSA MARINA; Bucci, C; DE FRANCISCIS, V; Fox, Gm; Jing, S; Coso, Om; Gutkind, Sj; Fusco, Alfredo; Santoro, M.
Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2)
2003 Carlomagno, Francesca; Vitagliano, D; Guida, T; Basolo, F; Castellone, Md; Melillo, ROSA MARINA; Fusco, Alfredo; Santoro, Massimo
Molecular heterogeneity of RET loss of function in Hirschsprung's disease
1996 Carlomagno, Francesca; DE VITA, Gabriella; Berlingieri, Mt; DE FRANCISCIS, V; Melillo, ROSA MARINA; Colantuoni, V; Kraus, Mh; DI FIORE, Pp; Fusco, Alfredo; Santoro, M.
Evolutionary conservation of the Eps8 gene and its mapping to human-chromosome 12q23-q24
1994 Wong, Wt; Carlomagno, Francesca; Druck, T; Barletta, C; Croce, Cm; Heubner, K; Kraus, Mh; DI FIORE, Pp
Titolo | Tipologia | Data di pubblicazione | Autore(i) | File |
---|---|---|---|---|
Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2). | 1.1 Articolo in rivista | 2003 | Carlomagno, F; Vitagliano, D; Guida, T; Basolo, F; Castellone, Md; Melillo, ROSA MARINA; Fusco, Alfredo; Santoro, Massimo | |
Genetic Alterations in differentiated thyroid cancer:what can be expected for gene expression profiling of thyroid carcinomas | 1.1 Articolo in rivista | 2003 | Santoro, Massimo; Melillo, ROSA MARINA; Carlomagno, Francesca; Castellone, MARIA DOMENICA; Vitagliano, Donata; Guida, Teresa; Vecchio, Giancarlo; Fusco, Alfredo | |
The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes | 1.1 Articolo in rivista | 2002 | Carlomagno, Francesca; Vitagliano, Donata; Guida, Teresa; Napolitano, M.; Vecchio, Giancarlo; Fusco, Alfredo; Gazit, A.; Levitzki, A.; Santoro, Massimo | |
The Insulin Receptor Substrate (IRS)-1 recruits Phosphatidylinositol 3-Kinase to Ret: evidence for a competition between Shc and IRS-1 for the binding to Ret. | 1.1 Articolo in rivista | 2001 | Melillo, ROSA MARINA; Carlomagno, Francesca; DE VITA, Gabriella; Formisano, Pietro; Vecchio, Giancarlo; Fusco, Alfredo; Billaud, M.; Santoro, Massimo | |
Constitutive and AP20187-induced ret activation in photoreceptors does not protect from light-induced damage | 1.1 Articolo in rivista | 2007 | M., Allocca; U., Di Vicino; M., Petrillo; F., Carlomagno; L., Domenici; Auricchio, Alberto; Carlomagno, Francesca | |
Basi molecolari delle nuove terapie: inibitori delle protein-chinasi. | 2.1 Contributo in volume (Capitolo o Saggio) | 2007 | Santoro, Massimo; Salvatore, G.; Carlomagno, F.; Fusco, Alfredo | |
Therapeutic strategies to target the receptor tyrosine kinase AXL in thyroid cancer | 4.2 Abstract in Atti di convegno | 2012 | Gnanaprakasam, Krisnamoorthy; Guida, Teresa; Visciano, Carla; Liotti, Federica; Carlomagno, Francesca; Melillo, ROSA MARINA | |
Ret-mediated mitogenesis requires Src kinase activity. | 1.1 Articolo in rivista | 1999 | Melillo, Rm; Barone, MARIA VITTORIA; Lupoli, G; Cirafici, Am; Carlomagno, F; Visconti, R; Matoskova, B; Di Fiore, Pp; Vecchio, G; Fusco, A; Santoro, M. | |
Receptor tyrosine kinase inhibitors in thyroid cancer. | 1.1 Articolo in rivista | 2008 | Castellone, Md; Carlomagno, Francesca; Salvatore, G; Santoro, Massimo | |
Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer. | 1.1 Articolo in rivista | 2013 | De Falco, V; Buonocore, Preziosa; Muthu, M; Torregrossa, L; Basolo, F; Billaud, M; Gozgit, Jm; Carlomagno, Francesca; Santoro, Massimo | |
Pros and cons of cellular studies in developing new drugs for thyroid cancers | 1.1 Articolo in rivista | 2008 | Salvatore, G.; Carlomagno, Francesca; Santoro, Massimo | |
Attacking cancer with molecularly targeted agents | 1.1 Articolo in rivista | 2013 | Santoro, Massimo; Carlomagno, Francesca | |
Activation of RET as a dominant transforming gene by germline mutatios of MEN2A and MEN2B | 1.1 Articolo in rivista | 1995 | Santoro, Massimo; Carlomagno, Francesca; A., Romano; D. D., Bottaro; N. A., Dathan; M., Grieco; Fusco, Alfredo; Vecchio, Giancarlo; B., Matoskova; M. H., Kraus; P. P., Di Fiore | |
Tyrosine 1062 of RET-MEN2A mediates activation of Akt (protein kinase B) and mitogen-activated protein kinase pathways leading to PC12 cell survival | 1.1 Articolo in rivista | 2000 | DE VITA, Gabriella; Melillo, ROSA MARINA; Carlomagno, Francesca; Visconti, R; Castellone, Md; Bellacosa, A; Billaud, M; Fusco, Alfredo; Tsichlis, Pn; Santoro, M. | |
Determination of the frequency of the common 657Del5 Nijmegen breakage syndrome mutation in the German population: no association with risk of breast cancer | 1.1 Articolo in rivista | 1999 | Carlomagno, Francesca; CHANG CLAUDE, J; Dunning, Am; Ponder, Baj | |
Mutations in the extracellular domain cause RET loss of function by a dominant negative mechanism | 1.1 Articolo in rivista | 1998 | Cosma, Mp; Cardone, M; Carlomagno, Francesca; Colantuoni, V. | |
Signalling of the Ret receptor tyrosine kinase through the c-Jun N-terminal Protein Kinases (JNKs): evidence for a divergence of the ERKs and JNKs pathways induced by Ret | 1.1 Articolo in rivista | 1998 | Chiariello, M; Visconti, R; Carlomagno, Francesca; Melillo, ROSA MARINA; Bucci, C; DE FRANCISCIS, V; Fox, Gm; Jing, S; Coso, Om; Gutkind, Sj; Fusco, Alfredo; Santoro, M. | |
Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2) | 1.1 Articolo in rivista | 2003 | Carlomagno, Francesca; Vitagliano, D; Guida, T; Basolo, F; Castellone, Md; Melillo, ROSA MARINA; Fusco, Alfredo; Santoro, Massimo | |
Molecular heterogeneity of RET loss of function in Hirschsprung's disease | 1.1 Articolo in rivista | 1996 | Carlomagno, Francesca; DE VITA, Gabriella; Berlingieri, Mt; DE FRANCISCIS, V; Melillo, ROSA MARINA; Colantuoni, V; Kraus, Mh; DI FIORE, Pp; Fusco, Alfredo; Santoro, M. | |
Evolutionary conservation of the Eps8 gene and its mapping to human-chromosome 12q23-q24 | 1.1 Articolo in rivista | 1994 | Wong, Wt; Carlomagno, Francesca; Druck, T; Barletta, C; Croce, Cm; Heubner, K; Kraus, Mh; DI FIORE, Pp |